146 lines
No EOL
43 KiB
XML
146 lines
No EOL
43 KiB
XML
<?xml version="1.0" encoding="utf-8"?>
|
|
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
|
|
|
|
<head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
|
|
<!-- AppResources meta begin -->
|
|
<meta name="paf-app-resources" content="" />
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- AppResources meta end -->
|
|
|
|
<!-- TemplateResources meta begin -->
|
|
<meta name="paf_template" content="" />
|
|
|
|
<!-- TemplateResources meta end -->
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK534230" /><meta name="ncbi_domain" content="statpearls" /><meta name="ncbi_report" content="printable" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK534230/?report=printable" /><meta name="ncbi_app" content="bookshelf" />
|
|
<!-- Logger end -->
|
|
|
|
<title>Adrenergic Drugs - StatPearls - NCBI Bookshelf</title>
|
|
|
|
<!-- AppResources external_resources begin -->
|
|
<link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>
|
|
|
|
<!-- AppResources external_resources end -->
|
|
|
|
<!-- Page meta begin -->
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="StatPearls [Internet]" /><meta name="citation_title" content="Adrenergic Drugs" /><meta name="citation_publisher" content="StatPearls Publishing" /><meta name="citation_date" content="2023/07/02" /><meta name="citation_author" content="Khashayar Farzam" /><meta name="citation_author" content="Ariel Kidron" /><meta name="citation_author" content="Anand D. Lakhkar" /><meta name="citation_pmid" content="30480963" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK534230/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Adrenergic Drugs" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="StatPearls Publishing" /><meta name="DC.Contributor" content="Khashayar Farzam" /><meta name="DC.Contributor" content="Ariel Kidron" /><meta name="DC.Contributor" content="Anand D. Lakhkar" /><meta name="DC.Date" content="2023/07/02" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK534230/" /><meta name="description" content="Adrenergic drugs are a broad class of medications that bind to adrenergic receptors throughout the body. These receptors include: alpha-1, alpha-2, beta-1, beta-2, beta-3. Adrenergic drugs will bind directly to one or more of these receptors to induce various physiologic effects. Adrenergic drugs must be classified based on the specific receptors they bind. This activity examines the pharmacology, various therapeutic effects, and adverse events that class members can exert, which covers a wide variety of clinical manifestations." /><meta name="og:title" content="Adrenergic Drugs" /><meta name="og:type" content="book" /><meta name="og:description" content="Adrenergic drugs are a broad class of medications that bind to adrenergic receptors throughout the body. These receptors include: alpha-1, alpha-2, beta-1, beta-2, beta-3. Adrenergic drugs will bind directly to one or more of these receptors to induce various physiologic effects. Adrenergic drugs must be classified based on the specific receptors they bind. This activity examines the pharmacology, various therapeutic effects, and adverse events that class members can exert, which covers a wide variety of clinical manifestations." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK534230/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-statpearls-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/statpearls/article-17240/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK534230/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_print.min.css" type="text/css" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} </style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/books.min.js"> </script>
|
|
|
|
<!-- Page meta end -->
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8E8B307D850E21000000000078006B.m_5" />
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4216701/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3984801/12930/3964959.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3411343/3882866.css" media="print" /></head>
|
|
<body class="book-part">
|
|
<div class="grid no_max_width">
|
|
<div class="col twelve_col nomargin shadow">
|
|
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
|
|
<div class="sysmessages">
|
|
<noscript>
|
|
<p class="nojs">
|
|
<strong>Warning:</strong>
|
|
The NCBI web site requires JavaScript to function.
|
|
<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
|
|
</p>
|
|
</noscript>
|
|
</div>
|
|
<!--/.sysmessage-->
|
|
<div class="wrap">
|
|
<div class="page">
|
|
<div class="top">
|
|
|
|
<div class="header">
|
|
|
|
|
|
</div>
|
|
|
|
|
|
|
|
<!--<component id="Page" label="headcontent"/>-->
|
|
|
|
</div>
|
|
<div class="content">
|
|
<!-- site messages -->
|
|
<div class="container content">
|
|
<div class="document">
|
|
<div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. </p></div></div></div>
|
|
<div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK534230_"><span class="title" itemprop="name">Adrenergic Drugs</span></h1><p class="contrib-group"><h4>Authors</h4><span itemprop="author">Khashayar Farzam</span><sup>1</sup>; <span itemprop="author">Ariel Kidron</span><sup>2</sup>; <span itemprop="author">Anand D. Lakhkar</span><sup>3</sup>.</p><h4>Affiliations</h4><div class="affiliation"><sup>1</sup> McMaster University</div><div class="affiliation"><sup>2</sup> Nova Southeastern College of Osteopathic Medicine</div><div class="affiliation"><sup>3</sup> Fresenius Kabi</div><p class="small">Last Update: <span itemprop="dateModified">July 2, 2023</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="article-17240.s1"><h2 id="_article-17240_s1_">Continuing Education Activity</h2><p>Adrenergic drugs are a broad class of medications that bind to adrenergic receptors throughout the body. These receptors include: alpha-1, alpha-2, beta-1, beta-2, beta-3. Adrenergic drugs will bind directly to one or more of these receptors to induce various physiologic effects. Adrenergic drugs must be classified based on the specific receptors they bind. This activity examines the pharmacology, various therapeutic effects, and adverse events that class members can exert, which covers a wide variety of clinical manifestations.</p><p>
|
|
<b>Objectives:</b>
|
|
<ul><li class="half_rhythm"><div>Identify the various actions of adrenergic medications based on the receptor to which they bind.</div></li><li class="half_rhythm"><div>Describe the various adverse effects of adrenergic drugs based on the binding site.</div></li><li class="half_rhythm"><div>Review the contraindications to various adrenergic drugs based on their preferred binding sites.</div></li><li class="half_rhythm"><div>Outline the importance of collaboration and coordination among the interprofessional team leading to improved patient care when using adrenergic agents.</div></li></ul>
|
|
<a href="https://www.statpearls.com/account/trialuserreg/?articleid=17240&utm_source=pubmed&utm_campaign=reviews&utm_content=17240" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Access free multiple choice questions on this topic.</a>
|
|
</p></div><div id="article-17240.s2"><h2 id="_article-17240_s2_">Indications</h2><p>Adrenergic drugs are a broad class of medications that bind to adrenergic receptors throughout the body. These receptors include: alpha-1, alpha-2, beta-1, beta-2, beta-3. Adrenergic drugs will bind directly to one or more of these receptors to induce various physiologic effects. Some drugs indirectly act at these receptors to induce certain effects.</p><p>Adrenergic drugs must be classified based on the specific receptors they bind. Direct-acting drugs, which are the primary focus of this article, include vasopressors, bronchodilators, and other drugs.<a class="bk_pop" href="#article-17240.r1">[1]</a> Examples of indirect drugs are amphetamines and cocaine.<a class="bk_pop" href="#article-17240.r2">[2]</a> </p><p>The major effects of agonist binding depend on their adrenergic receptors.<a class="bk_pop" href="#article-17240.r3">[3]</a><a class="bk_pop" href="#article-17240.r4">[4]</a><a class="bk_pop" href="#article-17240.r5">[5]</a> The broad categories are:</p><ul><li class="half_rhythm"><div>Alpha-1 receptor: Smooth muscle contraction, mydriasis</div></li><li class="half_rhythm"><div>Alpha-2 receptor: Mixed smooth muscle effects</div></li><li class="half_rhythm"><div>Beta-1 receptor: Increased cardiac chronotropic and inotropic effects</div></li><li class="half_rhythm"><div>Beta-2 receptor: Bronchodilation</div></li><li class="half_rhythm"><div>Beta-3 receptor: Increased lipolysis</div></li></ul><p>Examples of adrenergic drugs which selectively bind to alpha-1 receptors are phenylephrine and oxymetazoline. Selective alpha-2 receptor drugs include methyldopa and clonidine. The key beta-1 selective drug is dobutamine. Lastly, beta-2 selective drugs are bronchodilators, such as albuterol and salmeterol. </p><p>Adrenergic drugs can also be non-selective and bind to a combination of adrenergic receptors. Norepinephrine binds to the alpha-1, alpha-2, and beta-1 receptors. Dopamine binds to the alpha-1, alpha-2, beta-1 receptors, and also dopamine receptors. Epinephrine binds to all of the adrenergic receptors. These drugs bind to more adrenergic receptors when administered at higher doses, i.e., they can lose selectivity.</p><p>The following are key clinical indications of various adrenergic drugs: </p><p>
|
|
<b>Selective Drugs</b>
|
|
</p><p>
|
|
<b>Alpha-1 Receptor Agonists</b>
|
|
</p><ul><li class="half_rhythm"><div>Phenylephrine: FDA-approved as a decongestant and vasopressor. It has utility in cases of hypotension due to shock, such as septic shock.<a class="bk_pop" href="#article-17240.r6">[6]</a> Olson C. et al. reported on a patient who developed ischemic priapism from high doses of hydroxyzine hydrochloride (200 to 600 mg) for insomnia treatment. The patient received treatment with aspiration and 560 micrograms of intracavernosal phenylephrine, which led to detumescence.<a class="bk_pop" href="#article-17240.r7">[7]</a></div></li><li class="half_rhythm"><div>Oxymetazoline: FDA-approved as a decongestant and to treat rosacea. A patient with ptosis of the right eye caused by myasthenia gravis was treated with one eye drop of oxymetazoline (0.1%).<a class="bk_pop" href="#article-17240.r8">[8]</a> The ptosis was eliminated after 2 hours, and the effect lasted seven hours. This is a potential clinical use of oxymetazoline.</div></li></ul><p>
|
|
<b>Alpha-2 Receptor Agonists</b>
|
|
</p><ul><li class="half_rhythm"><div>Methyldopa: FDA-approved for hypertension and gestational hypertension.</div></li><li class="half_rhythm"><div>Clonidine: FDA-approved for treating hypertension and attention deficit hyperactivity disorder (ADHD). Non-FDA-approved indications include sleep disorders, post-traumatic stress disorder (PTSD), anxiety, restless leg syndrome, hot flashes associated with menopause, and other illnesses.<a class="bk_pop" href="#article-17240.r9">[9]</a></div></li><li class="half_rhythm"><div>Dexmedetomidine: This drug is indicated for sedation in the intensive care unit and does not cause respiratory depression. It causes an arousable state of sedation which is helpful during brain tumor surgery and implantation of deep brain stimulators because the patient is able to respond to neurological tests.<a class="bk_pop" href="#article-17240.r10">[10]</a></div></li></ul><p>
|
|
<b>Beta-1 Receptor Agonists</b>
|
|
</p><ul><li class="half_rhythm"><div>Dobutamine: Indicated for the treatment of cardiogenic shock and heart failure.<a class="bk_pop" href="#article-17240.r11">[11]</a> Patients in shock require hemodynamic support. Vasopressors (e.g., norepinephrine), inotropes (e.g., dobutamine), and IV fluid support are used for treatment. In most patients with shock (e.g., cardiogenic or septic), norepinephrine is commonly used to achieve appropriate arterial pressure. If the patient continues to have low tissue and organ perfusion, dobutamine can be added to increase cardiac output.<a class="bk_pop" href="#article-17240.r12">[12]</a></div></li></ul><p>
|
|
<b>Beta-2 Receptor Agonists</b>
|
|
</p><ul><li class="half_rhythm"><div>Bronchodilators: Indicated for treating obstructive lung disease, such as asthma.<a class="bk_pop" href="#article-17240.r13">[13]</a></div></li></ul><p>
|
|
<b>Beta-3 receptor Agonists</b>
|
|
</p><ul><li class="half_rhythm"><div>Mirabegron: This agent is indicated for treating overactive bladder, e.g., urinary incontinence and frequency. It is also indicated to treat pediatric (greater or equal to 3 years old) neurogenic detrusor overactivity.<a class="bk_pop" href="#article-17240.r14">[14]</a> </div></li></ul><p>
|
|
<b>Non-Selective Drugs</b>
|
|
</p><ul><li class="half_rhythm"><div>Norepinephrine: Indicated for the treatment of shock and hypotension</div></li><li class="half_rhythm"><div>Epinephrine (Adrenaline): Indicated for the treatment of cardiac arrest, anaphylaxis, and croup</div></li><li class="half_rhythm"><div>Dopamine: Indicated for the treatment of hypotension, bradycardia, and cardiac arrest.</div></li><li class="half_rhythm"><div>Isoprenaline: Indicated for treating bradycardia and heart block</div></li></ul><p>Many of these medications, especially the non-selective ones, are used in critical care and emergency settings. They are referred to as vasopressors. Side effects depend on the specific agent. However, changes in heart rate and blood pressure are the most common side effects. </p><p>Indirect-acting adrenergic drugs increase endogenous concentrations of norepinephrine and epinephrine through various mechanisms. Hence, their side effect profiles are similar to those seen with vasopressors. <a class="bk_pop" href="#article-17240.r15">[15]</a></p></div><div id="article-17240.s3"><h2 id="_article-17240_s3_">Mechanism of Action</h2><p>Adrenergic receptors, otherwise known as adreno-receptors, are classified as either alpha or beta receptors. Those two classes are further subdivided into alpha-1, alpha-2, beta-1, beta-2, and beta-3. Alpha-1 and alpha-2 receptors both have three subtypes. These receptors are all G-protein-coupled receptors. </p><p>Alpha-1 receptors are Gq-coupled receptors, whereas alpha-2 receptors are Gi-coupled receptors. Beta-2 and beta-3 are also Gi-coupled receptors. All beta receptors are also Gs-coupled receptors. </p><p>Agonist binding to the adrenergic receptors induces the following cellular mechanisms:</p><p>
|
|
<b>Alpha-1 Receptor</b>
|
|
</p><p>Phospholipase C is activated, which leads to the formation of inositol triphosphate (IP3) and diacylglycerol (DAG). As a result, intracellular calcium rises. </p><p>
|
|
<b>Alpha-2 Receptor</b>
|
|
</p><p>Adenylate cyclase is inactivated, which leads to a decrease in intracellular cyclic adenosine monophosphate (cAMP).</p><p>
|
|
<b>Beta-1 Receptor</b>
|
|
</p><p>Adenylate cyclase is activated, and intracellular cAMP increases.</p><p>
|
|
<b>Beta-2 Receptor</b>
|
|
</p><p>The adenylate cycle becomes activated through the Gs-protein-coupled receptors, and there is an increase in intracellular cAMP. Gi protein-coupled receptors are also activated, and this will decrease intracellular cAMP.<a class="bk_pop" href="#article-17240.r16">[16]</a><a class="bk_pop" href="#article-17240.r17">[17]</a></p><p>Investigators screened several cardiovascular drugs (e.g., methyldopa, amiodarone, doxazosin) and found that these affected in vitro Schistosoma mansoni viability.<a class="bk_pop" href="#article-17240.r18">[18]</a> This suggests that methyldopa might have antiparasitic properties.</p></div><div id="article-17240.s4"><h2 id="_article-17240_s4_">Administration</h2><p>Given adrenergic drugs are a broad class of medications, they are collectively available in almost every drug dosage form. Common methods of administration are oral, intravenous, intranasal, and topical. Dosages for beta-1 agonists such as dobutamine can begin with 0.5 to 1 mcg/kg/min and go up to 40 mcg/kg/min on the maximum end. The doses at the lower end can also be prescribed at 2.5 mcg/kg/min to 5 mcg/kg/min. While doses at the higher end can be prescribed at 5 mcg/kg/min to 20 mcg/kg/min. <a class="bk_pop" href="#article-17240.r19">[19]</a></p><p>While other medications such as clonidine (alpha-2 agonists) may be prescribed as transdermal patches with dosages of 0.1 mg/day to 0.3 mg/day while changing the patch every week. Clonidine can also be prescribed via an immediate-release tablet at 0.1 mg/day to 0.3 mg/day and an extended-release tablet with a dosage of 0.1 mg/day. Caution should be used when prescribing the medication to patients with renal failure as and it is recommended to begin with a low dose and increase as needed. <a class="bk_pop" href="#article-17240.r20">[20]</a></p></div><div id="article-17240.s5"><h2 id="_article-17240_s5_">Adverse Effects</h2><p>The adverse effects seen with adrenergic drugs are broad. The most common side effects are changes in heart rate and blood pressure. </p><p>Selective agonist binding to the alpha-1 receptor can lead to hypertension. Certain drugs that bind to the alpha-1 receptor, such as phenylephrine, may cause reflex bradycardia.<a class="bk_pop" href="#article-17240.r21">[21]</a></p><p>Drugs that selectively bind to alpha-2 receptors may cause hypotension, dry mouth, and sedation. At higher doses, respiratory depression and somnolence may occur. These effects are most pronounced with clonidine and similarly acting drugs.<a class="bk_pop" href="#article-17240.r20">[20]</a></p><p>Selective binding to beta-1 receptors commonly causes tachycardia, palpitations, and hypertension. Tachyarrhythmias and anxiety can also be common. High doses may induce dangerous arrhythmias. An example of a selective beta-1 receptor agonist is dobutamine.</p><p>Beta-2 receptor agonists can cause tremors, tachycardia, palpitations, and anxiety. Common examples are the various bronchodilator drugs such as albuterol and salmeterol.<a class="bk_pop" href="#article-17240.r22">[22]</a> Pediatric status asthmaticus is treated with continuous albuterol, which can cause hypokalemia.<a class="bk_pop" href="#article-17240.r23">[23]</a></p><p>Non-selective binding to the adrenergic receptors can cause different side effects that vary based on the specific agent as well as the dosage. The common non-selective agonists are norepinephrine, epinephrine, and isoproterenol (isoprenaline). Common side effects are tachycardia, hypertension, arrhythmias, palpitations, and anxiety. Norepinephrine is less likely to cause arrhythmias than some of the other pressor medications, probably because it is more alpha-1 receptor-selective as compared with the beta-1 receptor.<a class="bk_pop" href="#article-17240.r15">[15]</a></p></div><div id="article-17240.s6"><h2 id="_article-17240_s6_">Contraindications</h2><p>Alpha-1 receptor agonists are relatively contraindicated in those with the following medical conditions: hypertension, bradycardia, prostatic hyperplasia, and anyone using medications that may also increase blood pressure.</p><p>Alpha-2 receptor agonists should be used cautiously in anyone who has low blood pressure. Geriatric patients may be at increased risk of falls due to the sedating and hypotensive effects. </p><p>Beta-1 receptor agonists require caution in patients who have arrhythmias. </p><p>Beta-2 receptor agonists are relatively contraindicated in patients who have hypokalemia.</p><p>Norepinephrine is relatively contraindicated when using certain anesthetics. When dosing halothane or cyclopropane, there is an increased risk of dangerous arrhythmias.</p><p>Epinephrine is contraindicated in patients who have angle-closure glaucoma.<a class="bk_pop" href="#article-17240.r22">[22]</a><a class="bk_pop" href="#article-17240.r24">[24]</a></p></div><div id="article-17240.s7"><h2 id="_article-17240_s7_">Monitoring</h2><p>There is a broad variation in the therapeutic index of adrenergic drugs given a large number of medications. When prescribing beta-1 agonists, care should be taken to monitor hypertension as well as potential arrhythmias.<a class="bk_pop" href="#article-17240.r19">[19]</a> </p><p>While prescribing alpha-2 agonists, patients should be monitored for bradycardia, hypotension, and potential substance abuse.<a class="bk_pop" href="#article-17240.r20">[20]</a></p><p>Recent research has also counseled caution when administering beta-2 agonists as patients should be monitored for paradoxical bronchospasm, blood pressure, heart rate, and central nervous system effects.<a class="bk_pop" href="#article-17240.r25">[25]</a></p><p>There are case reports of patients abusing clonidine alone or with benzodiazepines and opioid analgesics. Clonidine may extend the opioid-induced euphoria and decrease the opioid dose needed for euphoria.<a class="bk_pop" href="#article-17240.r26">[26]</a></p></div><div id="article-17240.s8"><h2 id="_article-17240_s8_">Toxicity</h2><p>Adrenergic receptors all have drug antagonists. Alpha-blockers are not generally indicated for the treatment of alpha-agonist overdoses. Beta-blockers may be used to treat adverse effects arising from adrenergic receptor agonists acutely. Beta-blockers can treat tachycardia and hypertension that may occur from vasopressors. Toxicity should be monitored in the pediatric population when using beta-2 agonists as they can increase liver aminotransferase concentrations.<a class="bk_pop" href="#article-17240.r25">[25]</a></p><p>In addition, when prescribing alpha-2 agonists, there are instances where angioedema, atrioventricular (AV) block, and hypersensitivity may occur. Potential toxicities of beta-1 agonists may include tremors, headaches, and vomiting.<a class="bk_pop" href="#article-17240.r19">[19]</a><a class="bk_pop" href="#article-17240.r20">[20]</a></p></div><div id="article-17240.s9"><h2 id="_article-17240_s9_">Enhancing Healthcare Team Outcomes </h2><p>There are many types of adrenergic agents, and clinicians, including physicians, nurse practitioners, and physician assistants who prescribe these agents, should be aware of their side effects and contraindications. Management requires an interprofessional team approach to drug therapy with these drugs since they cover such a broad spectrum of indications and effects, both therapeutic and adverse. It is essential to consult with a pharmacist if there is any question about the use of an adrenergic agent; this can include drug-drug interactions, appropriate dosing based on the condition treated, and adverse event profile. Nurses can also access this resource as they will often administer the drugs inpatient and will need to know what signs to watch for in the event of an adverse reaction of any sort.</p><p>All interprofessional team embers must document any changes in patient status in the patient's medical record and communicate their findings to other team members so therapeutic adjustments can be made. An interprofessional team approach is vital to coordinate the care of patients taking these medications safely and effectively. [Level 5]</p></div><div id="article-17240.s10"><h2 id="_article-17240_s10_">Review Questions</h2><ul><li class="half_rhythm"><div>
|
|
<a href="https://www.statpearls.com/account/trialuserreg/?articleid=17240&utm_source=pubmed&utm_campaign=reviews&utm_content=17240" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Access free multiple choice questions on this topic.</a>
|
|
</div></li><li class="half_rhythm"><div>
|
|
<a href="https://www.statpearls.com/articlelibrary/commentarticle/17240/?utm_source=pubmed&utm_campaign=comments&utm_content=17240" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Comment on this article.</a>
|
|
</div></li></ul></div><div id="article-17240.s11"><h2 id="_article-17240_s11_">References</h2><dl class="temp-labeled-list"><dt>1.</dt><dd><div class="bk_ref" id="article-17240.r1">Giovannitti JA, Thoms SM, Crawford JJ. Alpha-2 adrenergic receptor agonists: a review of current clinical applications. <span><span class="ref-journal">Anesth Prog. </span>2015 Spring;<span class="ref-vol">62</span>(1):31-9.</span> [<a href="/pmc/articles/PMC4389556/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4389556</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25849473" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25849473</span></a>]</div></dd><dt>2.</dt><dd><div class="bk_ref" id="article-17240.r2">Ciccarone D. Stimulant abuse: pharmacology, cocaine, methamphetamine, treatment, attempts at pharmacotherapy. <span><span class="ref-journal">Prim Care. </span>2011 Mar;<span class="ref-vol">38</span>(1):41-58.</span> [<a href="/pmc/articles/PMC3056348/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3056348</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21356420" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21356420</span></a>]</div></dd><dt>3.</dt><dd><div class="bk_ref" id="article-17240.r3">Piascik MT, Perez DM. Alpha1-adrenergic receptors: new insights and directions. <span><span class="ref-journal">J Pharmacol Exp Ther. </span>2001 Aug;<span class="ref-vol">298</span>(2):403-10.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11454900" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11454900</span></a>]</div></dd><dt>4.</dt><dd><div class="bk_ref" id="article-17240.r4">Madden CJ, Tupone D, Cano G, Morrison SF. α2 Adrenergic receptor-mediated inhibition of thermogenesis. <span><span class="ref-journal">J Neurosci. </span>2013 Jan 30;<span class="ref-vol">33</span>(5):2017-28.</span> [<a href="/pmc/articles/PMC3711400/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3711400</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23365239" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23365239</span></a>]</div></dd><dt>5.</dt><dd><div class="bk_ref" id="article-17240.r5">Wachter SB, Gilbert EM. Beta-adrenergic receptors, from their discovery and characterization through their manipulation to beneficial clinical application. <span><span class="ref-journal">Cardiology. </span>2012;<span class="ref-vol">122</span>(2):104-12.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22759389" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22759389</span></a>]</div></dd><dt>6.</dt><dd><div class="bk_ref" id="article-17240.r6">Hatton RC, Winterstein AG, McKelvey RP, Shuster J, Hendeles L. Efficacy and safety of oral phenylephrine: systematic review and meta-analysis. <span><span class="ref-journal">Ann Pharmacother. </span>2007 Mar;<span class="ref-vol">41</span>(3):381-90.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17264159" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17264159</span></a>]</div></dd><dt>7.</dt><dd><div class="bk_ref" id="article-17240.r7">Olson C, Jhawar A, Elfessi Z, Doyle R. Hydroxyzine-induced priapism. <span><span class="ref-journal">Am J Emerg Med. </span>2021 Oct;<span class="ref-vol">48</span>:375.e5-375.e6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33836933" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33836933</span></a>]</div></dd><dt>8.</dt><dd><div class="bk_ref" id="article-17240.r8">Cooper J, Yang D. Case Report: Treatment of Myasthenic Ptosis with Topical Ocular Oxymetazoline. <span><span class="ref-journal">Optom Vis Sci. </span>2021 Nov 01;<span class="ref-vol">98</span>(11):1317-1320.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34510144" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34510144</span></a>]</div></dd><dt>9.</dt><dd><div class="bk_ref" id="article-17240.r9">Ming X, Mulvey M, Mohanty S, Patel V. Safety and efficacy of clonidine and clonidine extended-release in the treatment of children and adolescents with attention deficit and hyperactivity disorders. <span><span class="ref-journal">Adolesc Health Med Ther. </span>2011;<span class="ref-vol">2</span>:105-12.</span> [<a href="/pmc/articles/PMC3926778/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3926778</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24600280" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24600280</span></a>]</div></dd><dt>10.</dt><dd><div class="bk_ref" id="article-17240.r10">Tasbihgou SR, Barends CRM, Absalom AR. The role of dexmedetomidine in neurosurgery. <span><span class="ref-journal">Best Pract Res Clin Anaesthesiol. </span>2021 Jul;<span class="ref-vol">35</span>(2):221-229.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34030806" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34030806</span></a>]</div></dd><dt>11.</dt><dd><div class="bk_ref" id="article-17240.r11">Dubin A, Lattanzio B, Gatti L. The spectrum of cardiovascular effects of dobutamine - from healthy subjects to septic shock patients. <span><span class="ref-journal">Rev Bras Ter Intensiva. </span>2017 Oct-Dec;<span class="ref-vol">29</span>(4):490-498.</span> [<a href="/pmc/articles/PMC5764562/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5764562</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29340539" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29340539</span></a>]</div></dd><dt>12.</dt><dd><div class="bk_ref" id="article-17240.r12">Jentzer JC, Hollenberg SM. Vasopressor and Inotrope Therapy in Cardiac Critical Care. <span><span class="ref-journal">J Intensive Care Med. </span>2021 Aug;<span class="ref-vol">36</span>(8):843-856.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32281470" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32281470</span></a>]</div></dd><dt>13.</dt><dd><div class="bk_ref" id="article-17240.r13">Matera MG, Rinaldi B, Page C, Rogliani P, Cazzola M. Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease. <span><span class="ref-journal">Expert Opin Drug Metab Toxicol. </span>2018 Oct;<span class="ref-vol">14</span>(10):1101-1111.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30261755" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30261755</span></a>]</div></dd><dt>14.</dt><dd><div class="bk_ref" id="article-17240.r14">Keam SJ. Mirabegron: Pediatric First Approval. <span><span class="ref-journal">Paediatr Drugs. </span>2021 Jul;<span class="ref-vol">23</span>(4):411-415.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34056686" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34056686</span></a>]</div></dd><dt>15.</dt><dd><div class="bk_ref" id="article-17240.r15">Smith MD, Maani CV. <span class="ref-journal">StatPearls [Internet].</span> StatPearls Publishing; Treasure Island (FL): Dec 11, 2024. Norepinephrine. [<a href="https://pubmed.ncbi.nlm.nih.gov/30725944" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30725944</span></a>]</div></dd><dt>16.</dt><dd><div class="bk_ref" id="article-17240.r16">Seiler R, Rickenbacher A, Shaw S, Balsiger BM. alpha- and beta-adrenergic receptor mechanisms in spontaneous contractile activity of rat ileal longitudinal smooth muscle. <span><span class="ref-journal">J Gastrointest Surg. </span>2005 Feb;<span class="ref-vol">9</span>(2):227-35.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15694819" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15694819</span></a>]</div></dd><dt>17.</dt><dd><div class="bk_ref" id="article-17240.r17">Ruiz-Medina BE, Cadena-Medina DA, Esparza E, Arrieta AJ, Kirken RA. Isoproterenol-induced beta-2 adrenergic receptor activation negatively regulates interleukin-2 signaling. <span><span class="ref-journal">Biochem J. </span>2018 Sep 18;<span class="ref-vol">475</span>(18):2907-2923.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30120106" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30120106</span></a>]</div></dd><dt>18.</dt><dd><div class="bk_ref" id="article-17240.r18">Porto R, Mengarda AC, Cajas RA, Salvadori MC, Teixeira FS, Arcanjo DDR, Siyadatpanah A, Pereira ML, Wilairatana P, Moraes J. Antiparasitic Properties of Cardiovascular Agents against Human Intravascular Parasite <em>Schistosoma mansoni</em>. <span><span class="ref-journal">Pharmaceuticals (Basel). </span>2021 Jul 16;<span class="ref-vol">14</span>(7)</span> [<a href="/pmc/articles/PMC8308662/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8308662</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34358112" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34358112</span></a>]</div></dd><dt>19.</dt><dd><div class="bk_ref" id="article-17240.r19">Ashkar H, Adnan G, Patel P, Makaryus AN. <span class="ref-journal">StatPearls [Internet].</span> StatPearls Publishing; Treasure Island (FL): Feb 23, 2024. Dobutamine. [<a href="https://pubmed.ncbi.nlm.nih.gov/29262042" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29262042</span></a>]</div></dd><dt>20.</dt><dd><div class="bk_ref" id="article-17240.r20">Yasaei R, Saadabadi A. <span class="ref-journal">StatPearls [Internet].</span> StatPearls Publishing; Treasure Island (FL): Jul 17, 2023. Clonidine. [<a href="https://pubmed.ncbi.nlm.nih.gov/29083638" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29083638</span></a>]</div></dd><dt>21.</dt><dd><div class="bk_ref" id="article-17240.r21">Atkinson HC, Potts AL, Anderson BJ. Potential cardiovascular adverse events when phenylephrine is combined with paracetamol: simulation and narrative review. <span><span class="ref-journal">Eur J Clin Pharmacol. </span>2015 Aug;<span class="ref-vol">71</span>(8):931-8.</span> [<a href="/pmc/articles/PMC4500855/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4500855</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26022219" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26022219</span></a>]</div></dd><dt>22.</dt><dd><div class="bk_ref" id="article-17240.r22">Almadhoun K, Sharma S. <span class="ref-journal">StatPearls [Internet].</span> StatPearls Publishing; Treasure Island (FL): Apr 28, 2023. Bronchodilators. [<a href="https://pubmed.ncbi.nlm.nih.gov/30085570" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30085570</span></a>]</div></dd><dt>23.</dt><dd><div class="bk_ref" id="article-17240.r23">Cox C, Patel K, Cantu R, Akmyradov C, Irby K. Hypokalemia Measurement and Management in Patients With Status Asthmaticus on Continuous Albuterol. <span><span class="ref-journal">Hosp Pediatr. </span>2022 Feb 01;<span class="ref-vol">12</span>(2):198-204.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35018439" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35018439</span></a>]</div></dd><dt>24.</dt><dd><div class="bk_ref" id="article-17240.r24">Roehrborn CG, Schwinn DA. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. <span><span class="ref-journal">J Urol. </span>2004 Mar;<span class="ref-vol">171</span>(3):1029-35.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14767264" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14767264</span></a>]</div></dd><dt>25.</dt><dd><div class="bk_ref" id="article-17240.r25">Johnson DB, Merrell BJ, Bounds CG. <span class="ref-journal">StatPearls [Internet].</span> StatPearls Publishing; Treasure Island (FL): Jan 10, 2024. Albuterol. [<a href="https://pubmed.ncbi.nlm.nih.gov/29489143" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29489143</span></a>]</div></dd><dt>26.</dt><dd><div class="bk_ref" id="article-17240.r26">Mitchell BG, Lee J. Case Report: Concurrent Clonidine Abuse and Opioid Use Disorder. <span><span class="ref-journal">J Psychoactive Drugs. </span>2021 Sep-Oct;<span class="ref-vol">53</span>(4):373-377.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33814003" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33814003</span></a>]</div></dd></dl></div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_top_margin">
|
|
<b>Disclosure: </b>Khashayar Farzam declares no relevant financial relationships with ineligible companies.</p></div></dd><dt></dt><dd><div><p class="no_top_margin">
|
|
<b>Disclosure: </b>Ariel Kidron declares no relevant financial relationships with ineligible companies.</p></div></dd><dt></dt><dd><div><p class="no_top_margin">
|
|
<b>Disclosure: </b>Anand Lakhkar declares no relevant financial relationships with ineligible companies.</p></div></dd></dl></div></div></div>
|
|
<div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 2025, StatPearls Publishing LLC.<p class="small">
|
|
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
|
|
(<a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=uri">
|
|
http://creativecommons.org/licenses/by-nc-nd/4.0/
|
|
</a>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
|
|
</p></div><div class="small"><span class="label">Bookshelf ID: NBK534230</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/30480963" title="PubMed record of this page" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">30480963</a></span></div></div></div>
|
|
|
|
</div>
|
|
</div>
|
|
</div>
|
|
<div class="bottom">
|
|
|
|
<div id="NCBIFooter_dynamic">
|
|
<!--<component id="Breadcrumbs" label="breadcrumbs"/>
|
|
<component id="Breadcrumbs" label="helpdesk"/>-->
|
|
|
|
</div>
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
</div>
|
|
</div>
|
|
<!--/.page-->
|
|
</div>
|
|
<!--/.wrap-->
|
|
</div><!-- /.twelve_col -->
|
|
</div>
|
|
<!-- /.grid -->
|
|
|
|
<span class="PAFAppResources"></span>
|
|
|
|
<!-- BESelector tab -->
|
|
|
|
|
|
|
|
<noscript><img alt="statistics" src="/stat?jsdisabled=true&ncbi_db=books&ncbi_pdid=book-part&ncbi_acc=NBK534230&ncbi_domain=statpearls&ncbi_report=printable&ncbi_type=fulltext&ncbi_objectid=&ncbi_pcid=/NBK534230/?report=printable&ncbi_app=bookshelf" /></noscript>
|
|
|
|
|
|
<!-- usually for JS scripts at page bottom -->
|
|
<!--<component id="PageFixtures" label="styles"></component>-->
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal107 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3879255/4121861/3501987/4008961/3893018/3821238/3400083/3426610.js" snapshot="books"></script></body>
|
|
</html> |